BITR-2101

N/A

Report date: 2023/08/22 17:31:23

Base Information

Drug NameBITR-2101
Drug Alias NameBITR-2101BIR-2101BITT2101BITT-2101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 1B antagonists
TargetsTumor necrosis factor receptor superfamily member 1B
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousLymphoma, Non-Hodgkin +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoston Immune Technologies & Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesBoston Immune Technologies & Therapeutics
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousLymphoma, Non-Hodgkin
Inactive IndicationsNeoplasmsInfections

Other Information

ATC CodeN/A
Related LinksN/A